Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.64 |
| ▸ | ANPEP | P15144 | 1/20 | 0.64 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 2/20 | 0.59 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3904609 | 1.00 | MMP2 (0.64) | MMP2ANPEPCASP3MMP9FKBP1A | |
| SCHEMBL2769758 | 0.93 | MMP2 (0.65) | MMP2ANPEPCASP3MMP9FKBP1A | |
| SCHEMBL7085726 | 0.88 | CASP3 (0.58) | MMP2ANPEPCASP3MMP9ALDH1A1 | |
| SCHEMBL7085725 | 0.88 | CASP3 (0.58) | MMP2ANPEPCASP3MMP9ALDH1A1 | |
| SCHEMBL20291414 | 0.88 | BRD4 (0.66) | MMP2CASP3MMP9ALDH1A1KMT2A | |
| SCHEMBL5885922 | 0.87 | ALDH1A1 (0.70) | MMP2ANPEPCASP3ALDH1A1KMT2A | |
| SCHEMBL5885924 | 0.87 | ALDH1A1 (0.70) | MMP2ANPEPCASP3ALDH1A1KMT2A | |
| SCHEMBL16763211 | 0.86 | CASP3 (0.60) | MMP2ANPEPCASP3MMP9ALDH1A1 | |
| SCHEMBL21442025 | 0.86 | LMNA (0.62) | CASP3FKBP1ATDP1ALDH1A1KMT2A | |
| SCHEMBL3115162 | 0.86 | HCRTR1 (0.62) | MMP2CASP3MMP9FKBP1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
| EP-1778717-A4 | CELL ADHESION INHIBITORS | BIOGEN IDEC INC (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1778717-A2 | CELL ADHESION INHIBITORS | Biogen Idec MA, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7196112-B2 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196112-B2 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070066533-A1 | Cell adhesion inhibitors | LEE WEN-CHERNG | 2007-03-22 | — | — | US | disclosed |
| US-20060166961-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2006-07-27 | — | — | US | disclosed |
| US-7034043-B2 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2006019632-A2 | CELL ADHESION INHIBITORS | BIOGEN IDEC MA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014966-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. | 2006-01-19 | — | — | US | disclosed |
| US-20040132809-A1 | Cell adhesion inhibitors | BIOGEN, INC. | 2004-07-08 | — | — | US | disclosed |
| US-6630503-B1 | Non-peptidic sulfonamide compounds that specifically inhibit the binding of ligands to VLA-4 for inhibition, prevention and suppression of VLA-4-mediated cell adhesion and pathologies such as inflammation and immune reactions | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| EP-1265606-A4 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1265606-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 2002-12-18 | — | — | EP | disclosed |
| CN-1377268-A | Cell adhesion inhibitors | BIOGEN INC (US) | 2002-10-30 | — | — | CN | disclosed |
| WO-2001012186-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | VCAM1, ICAM1, EPCAM | MMP2 1428/4885ANPEP 2002/4885CASP3 1655/4885 |
| US-20070066533-A1 | Cell adhesion inhibitors | VCAM1, EPCAM, ICAM1 | MMP2 611/4885ANPEP 770/4885CASP3 1776/4885 |
| US-20060166961-A1 | Cell adhesion inhibitors | VCAM1, ICAM1, EPCAM | MMP2 928/4885ANPEP 2223/4885CASP3 2169/4885 |
| US-20060014966-A1 | Cell adhesion inhibitors | VCAM1, EPCAM, ICAM1 | MMP2 611/4885ANPEP 770/4885CASP3 1776/4885 |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | MMP2 1229/4885ANPEP 107/4885CASP3 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.